AR122352A1 - Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este - Google Patents
Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de esteInfo
- Publication number
- AR122352A1 AR122352A1 ARP200103421A ARP200103421A AR122352A1 AR 122352 A1 AR122352 A1 AR 122352A1 AR P200103421 A ARP200103421 A AR P200103421A AR P200103421 A ARP200103421 A AR P200103421A AR 122352 A1 AR122352 A1 AR 122352A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- pyrazolil
- disubstituted
- steroid
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En el presente documento se proporcionan métodos para tratar la depresión, tal como el trastorno depresivo mayor, en un sujeto que lo necesite, que comprenden la administración al sujeto de una cantidad eficaz del compuesto de fórmula (1) o de una sal farmacéuticamente aceptable de este.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962944144P | 2019-12-05 | 2019-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR122352A1 true AR122352A1 (es) | 2022-09-07 |
Family
ID=74106152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200103421A AR122352A1 (es) | 2019-12-05 | 2020-12-09 | Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230018765A1 (es) |
EP (1) | EP4069250A1 (es) |
JP (1) | JP2023504517A (es) |
KR (1) | KR20220112803A (es) |
CN (1) | CN114761019A (es) |
AR (1) | AR122352A1 (es) |
AU (1) | AU2020395246A1 (es) |
CA (1) | CA3163556A1 (es) |
IL (1) | IL293510A (es) |
MX (1) | MX2022006533A (es) |
TW (1) | TW202133863A (es) |
WO (1) | WO2021113786A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112472814A (zh) | 2012-01-23 | 2021-03-12 | 萨奇治疗股份有限公司 | 神经活性类固醇制剂和治疗中枢神经系统障碍的方法 |
US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US10774108B2 (en) | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
AU2017315682B2 (en) | 2016-08-23 | 2021-11-11 | Sage Therapeutics, Inc. | A crystalline 19-nor C3, 3-disubstituted C21-n-pyrazolyl steroid |
US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019051264A1 (en) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS AND METHODS OF USE |
TW201930269A (zh) * | 2018-01-12 | 2019-08-01 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
JP2021527092A (ja) * | 2018-06-12 | 2021-10-11 | セージ セラピューティクス, インコーポレイテッド | 19−ノルc3,3−二置換c21−n−ピラゾリルステロイドおよびその使用方法 |
-
2020
- 2020-12-05 EP EP20834042.2A patent/EP4069250A1/en active Pending
- 2020-12-05 MX MX2022006533A patent/MX2022006533A/es unknown
- 2020-12-05 CN CN202080084566.0A patent/CN114761019A/zh active Pending
- 2020-12-05 JP JP2022533122A patent/JP2023504517A/ja active Pending
- 2020-12-05 WO PCT/US2020/063507 patent/WO2021113786A1/en active Application Filing
- 2020-12-05 CA CA3163556A patent/CA3163556A1/en active Pending
- 2020-12-05 US US17/782,362 patent/US20230018765A1/en active Pending
- 2020-12-05 IL IL293510A patent/IL293510A/en unknown
- 2020-12-05 KR KR1020227022451A patent/KR20220112803A/ko active Search and Examination
- 2020-12-05 AU AU2020395246A patent/AU2020395246A1/en active Pending
- 2020-12-07 TW TW109143121A patent/TW202133863A/zh unknown
- 2020-12-09 AR ARP200103421A patent/AR122352A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202133863A (zh) | 2021-09-16 |
EP4069250A1 (en) | 2022-10-12 |
US20230018765A1 (en) | 2023-01-19 |
CN114761019A (zh) | 2022-07-15 |
AU2020395246A1 (en) | 2022-06-16 |
KR20220112803A (ko) | 2022-08-11 |
CA3163556A1 (en) | 2021-06-10 |
IL293510A (en) | 2022-08-01 |
MX2022006533A (es) | 2023-03-01 |
JP2023504517A (ja) | 2023-02-03 |
WO2021113786A1 (en) | 2021-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR122352A1 (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este | |
CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
CO2018012482A2 (es) | Formulaciones de un inhibidor de lsd1 | |
CO2017001493A2 (es) | Kits que comprenden inhibidores tigit y agentes anticáncer | |
CL2020000299A1 (es) | Compuestos, composiciones y métodos. | |
CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
CL2020002512A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak. | |
CU20150096A7 (es) | Compuestos de amida y composición farmacéutica para el tratamiento de vih | |
AR101740A1 (es) | Terapia de combinación y composiciones | |
MX2020013557A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. | |
UY38160A (es) | Partículas implantables y métodos relacionados | |
CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
CL2020002915A1 (es) | Composiciones para el tratamiento de condiciones de la piel | |
CO2022000481A2 (es) | Inhibidores de enzimas | |
NI201800071A (es) | Compuestos de isoindol | |
CL2019002340A1 (es) | Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1. | |
CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
CL2019003393A1 (es) | Virus oncolíticos y método. | |
CL2023000289A1 (es) | Combinaciones para el tratamiento de cáncer | |
CL2020002544A1 (es) | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret | |
MX2020004678A (es) | Uso de profarmacos de riluzol para tratar ataxias. | |
CL2020003380A1 (es) | Compuestos que aumentan la actividad del proteosoma. | |
ECSP13012524A (es) | Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia |